ProQR Therapeutics N.V.

Overview

Compare with another stock.

• TickerPRQR on Nasdaq¹
• IndustryPharmaceutical Preparations¹
• HeadquartersP7¹
• Incorporated inNetherlands³
• Business addressZernikedreef 9, Leiden³
• Filer categoryAccelerated filer³

See how the biggest companies compare on our leaderboards

We are a clinical-stage biotechnology company focused on advancing a pipeline of RNA editing therapeutics based on our proprietary Axiomer RNA-editing platform. Our lead program, AX-0810 for cholestatic diseases targeting NTCP, is currently being evaluated in a Phase 1 clinical trial in healthy volunteers. With funding from the Rett Syndrome Research Trust, we are also advancing AX-2402 targeting methyl CpG binding protein 2 mutations for Rett syndrome, a severe neurodevelopmental disorder. Additional pipeline programs include AX-2911 targeting PNPLA3 for metabolic dysfunction-associated steatohepatitis, AX-1412 targeting the B4GALT1 gene for CVDs, as well as a number of additional discovery-stage programs. In addition to our own pipeline programs, we have a partnership with Lilly, currently focused on up to 10 targets based on our Axiomer platform. Our ongoing discovery and screening ef…⁴ From its latest annual report

Corporate structure

ProQR Therapeutics N.V. sits at the top of its group. 1 entity on record. Switch between the flow chart and the network, and select any entity to see its details.

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

Leadership

Who has led ProQR Therapeutics N.V., and when. Pick a name to see everywhere that person has worked.

• Chief financial officerDennis Hom Mar 18, 2026 to now¹¹

Former names

• ProQR Therapeutics B.V.Jul 11, 2014 to Oct 3, 2014³

Calendar

Coming up

1. Nov 5, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($0.12) a share, on Nov 6, 2025.²⁰

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

164 filings to the SEC since October 2021: 5 annual reports, 18 insider forms, 32 large holders, 109 other. The latest 20:

1. Sep 23, 20266-K EDGAR
2. Sep 9, 20266-K EDGAR
3. Aug 13, 20266-K EDGAR
4. Aug 13, 20266-K EDGAR
5. Aug 3, 20264 OWNERSHIP DOCUMENT EDGAR
6. Jul 29, 2026SCHEDULE 13G EDGAR
7. Jul 29, 2026SCHEDULE 13D/A EDGAR
8. Jul 24, 2026SCHEDULE 13G/A EDGAR
9. Jul 21, 20264 OWNERSHIP DOCUMENT EDGAR
10. Jul 15, 2026EFFECT EDGAR
11. Jul 15, 2026424B5 EDGAR
12. Jul 15, 2026SCHEDULE 13G/A EDGAR
13. Jul 13, 20264 OWNERSHIP DOCUMENT EDGAR
14. Jul 8, 20264 OWNERSHIP DOCUMENT EDGAR
15. Jul 6, 2026F-3 EDGAR
16. Jun 30, 2026SCHEDULE 13D/A EDGAR
17. Jun 30, 20264/A OWNERSHIP DOCUMENT EDGAR
18. Jun 30, 20264 OWNERSHIP DOCUMENT EDGAR
19. Jun 26, 20266-K EDGAR
20. Jun 26, 2026424B5 EDGAR

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

5 open-market trades by officers, directors and large owners since October 2021: 5 buys and 0 sales. Grants, option exercises and gifts are left out.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

• Aberdeen Group plcSCHEDULE 13G, 1 filing Jul 29, 2026²¹
• VAN HERK INVESTMENTS B.V.SCHEDULE 13D/A, 12 filings Sep 14, 2023 to Jul 29, 2026²²
• Eli Lilly and CompanySCHEDULE 13G/A, 2 filings Dec 23, 2022 to Jul 24, 2026²³
• Privium Fund Management B.V.SCHEDULE 13G/A, 2 filings Jan 20, 2026 to Jul 15, 2026²⁴
• Adage Capital Management, L.P.SCHEDULE 13G/A, 3 filings Feb 12, 2025 to Aug 12, 2025²⁵
• RTW INVESTMENTS, LPSC 13G/A, 2 filings Feb 14, 2022 to Feb 14, 2023²⁶
• ADAGE CAPITAL PARTNERS GP, L.L.C.SC 13G/A, 2 filings Feb 10, 2022 to Feb 9, 2023²⁷
• Aescap Life Sciences StichtingSC 13G/A, 2 filings Feb 4, 2022 to Feb 9, 2023²⁸
• FMR LLCSC 13G/A, 2 filings Feb 9, 2022 to Feb 9, 2023²⁹
• Goldman SachsSC 13G/A, 2 filings Feb 7, 2022 to Feb 8, 2023³⁰
• Wellington Management CompanySC 13G/A, 2 filings Feb 4, 2022 to May 9, 2022³¹

SEC filer profile

How ProQR Therapeutics N.V. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

• Name on EDGARProQR Therapeutics N.V.¹
• CIK0001612940
• Filer statusAccelerated filer not an emerging growth company; not a shell company⁴
• Incorporated inNetherlands⁴
• Fiscal year endsDecember 31¹
• Industry code (SIC)2834 Pharmaceutical Preparations¹
• SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance¹
• Business addressZernikedreef 9, Leiden, Netherlands¹
• Phone31 88 166 7000¹
• Shares outstanding105,361,064 shares as of Dec 31, 2025⁴
• AuditorKPMG Accountants N.V., Amstelveen, the Netherlands PCAOB ID 1012; it also attests to the company’s internal control over financial reporting⁴
• On EDGAR sinceJul 11, 2014¹
• Filings389 in all: 6-K (184), SC 13G/A (49), 424B5 (23), SC 13G (20), CORRESP (13), 20-F (12), UPLOAD (12), 3 (11)¹
  All 29 form types

  EFFECT (10), F-3 (10), SCHEDULE 13D/A (7), 4 (6), CT ORDER (5), SCHEDULE 13G/A (5), F-1/A (3), S-8 (3), SCHEDULE 13G (3), 6-K/A (2), 144 (1), 4/A (1), 424B4 (1), 8-A12B (1), CERTNAS (1), DRS (1), F-1 (1), F-1MEF (1), FWP (1), RW (1), SCHEDULE 13D (1)

• Latest filingsAnnual report (20-F) Mar 12, 2026

Securities registered for trading

From the cover page of the 20-F filed Mar 12, 2026 (Section 12(b) of the Exchange Act).⁴